Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-CLTX extracellular vesicles
- Development stage
- Preclinical
- Lead developer
- Mayo Clinic
- Modality
- Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intratumoral
01
Overview
CAR-CLTX extracellular vesicles (EXTH-145) are a novel therapeutic modality consisting of extracellular vesicles (EVs) derived from neutrophils that have been engineered to express a chimeric antigen receptor (CAR) incorporating chlorotoxin (CLTX). These EVs are produced by differentiating induced pluripotent stem cells (iPSCs) into neutrophils after inserting CAR-CLTX DNA into a safe harbor locus. The resulting EVs retain the tumor-targeting capabilities of the parent CAR-neutrophils, specifically targeting glioblastoma cells via the CLTX domain. In addition to direct CAR-mediated targeting, these EVs carry a cargo of anti-tumor proteins and tumor-suppressive microRNAs (such as miR-182) that induce apoptosis and modulate various signaling pathways, including Jak-STAT, Hedgehog, and NK cell-mediated cytotoxicity. This approach aims to provide the therapeutic benefits of CAR-neutrophils while minimizing the systemic off-target effects associated with whole-cell administration.
- Other names
- CAR-CLTX EVsCAR-CLTX neutrophil-derived extracellular vesiclesCAR-engineered extracellular vesicles
02
Targets
Glioma-associated chlorotoxin-binding surface complex
Beyond the preview
Go deeper on CAR-CLTX extracellular vesicles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-CLTX extracellular vesicles.